Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1
US11845781B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2023 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Mar 10, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.